Intradermal | Our intradermal lead product Bella-mu simplifies intradermal administration of up to 1 mL, offering an easier learning curve compared to the Mantoux technique. It’s an ideal solution for companies developing cancer vaccines that seek enhanced immune responses, reduced antigen requirements, and improved patient compliance. Bella-mu is particularly effective for vaccines utilizing neoantigens, whole-tumor cells, mRNA, DNA, peptides, viral vectors, or dendritic cells.

Suprachoroidal | Our ophthalmic lead product Bella-Vue is designed to facilitate suprachoroidal injections for the precise delivery of small molecules or biologics to the back of the eye. This technology is particularly valuable for companies developing ophthalmic therapies targeting the retina, such as treatments for wet and dry age-related macular degeneration (AMD), diabetic retinopathy, retinal detachment, retinitis pigmentosa, or macular edema.

As a legal manufacturer of intradermic needles, Uneedle provides easy to learn and reliable injection into superficial tissues.
The Uneedle organisation is full scope ISO13485 certified for design and manufacturing of silicon microneedles.
Our expertise is to design and manufacture needles that are very short, sharp and precise, based on proprietary technology that is CE marked and FDA approved, making use of innovative semiconductor manufacturing processes in our in-house GMP compliant  manufacturing site in The Netherlands (EU).